Skip to main content Accessibility help

Dimensions of Outcome with Clozapine

  • Herbert Y. Meltzer (a1)


Various outcome measures following clozapine administration to neuroleptic-resistant schizophrenic patients are considered. The importance of a multidimensional perspective is emphasised. There was significant improvement in positive symptoms, some negative symptoms, quality of life, some types of cognitive function (e.g. semantic memory), extrapyramidal function, and tardive dyskinesia. Readmission to hospital, and family burden were markedly reduced, which achieved significant savings in the cost of treatment. Compliance with clozapine and weekly blood testing can be achieved in the majority of treatment-resistant cases. These benefits may occur independently of each other.



Hide All
Andreasen, N. C. (1982) Negative symptoms in schizophrenia: definition and reliability. Archives of General Psychiatry, 39, 784788.
Caine, E. D., Polinsky, R. J., Kartzinel, R., et al (1979) The trial use of clozapine for abnormal involuntary movement disorders. American Journal of Psychiatry, 136, 317320.
Casey, D. E. (1989) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology Bulletin, 99, S47S53.
Chapman, L. J. (1980) Recent advances in the study of schizophrenic cognition. In Special Report: Schizophrenia 1980, pp. 6981. Washington, DC: Department of Health and Human Services.
Claghorn, J., Honigfeld, G., Abuzzahab, F. S., et al (1987) The risks and benefits of clozapine versus chlorpromazine. Journal of Clinical Psychopharmacology, 7, 377384.
Cohen, B. M., Keck, P. E., Satlin, A., et al (1991) Prevalence and severity of akathisia in patients on clozapine. Biological Psychiatry, 29, 12151219.
Crow, T. J. (1980) Molecular pathology of schizophrenia: more than one disease process? British Medical Journal, 280, 6668.
Endicott, J. & Spitzer, R. L. (1978) A diagnostic interview: the schedule for affective disorders and schizophrenia. Archives of General Psychiatry, 35, 837844.
Gerlach, J., Thorsen, K. & Fog, R. (1975) Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients. Psychopharmacologia, 40, 13411350.
Gerlach, J. & Simmelsgaard, H. (1978) Tardive dyskinesia during and following treatment with haloperidol + biperiden, thioridazine and dopamine. Psychopharmacology, 59, 105112.
Guy, W. (1976) ECDEV Assessment Manual for Psychopharmacology, revised DHEW Pub. No. (ADM) 78-388. Rockville, MD: National Institute of Mental Health.
Hemsley, D. R. (1987) An experimental psychological model for schizophrenia. In Search for the Causes of Schizophrenia (eds Hafner, H., Gattaz, W. F. & Janzavik, W.). New York: Springer-Verlag.
Heinrichs, D. W., Hanlon, T. E. & Carpenter, W. T. Jr (1984) The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin, 10, 388398.
Honigfeld, G. & Klelt, G. (1965) The nurses’ observation scale for in-patient evaluation (NOSIE-30): A new scale for measuring improvement in chronic schizophrenia. Journal of Clinical Psychology, 21, 6571.
Honigfeld, G. & Patin, J. (1990) Predictors of response to clozapine therapy. Psychopharmacology, 99, S64S67.
Kane, J., Honigfeld, G., Singer, J., et al (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789796.
Kay, S. G., Opler, L. A. & Lindenmayer, J.-P. (1988) Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenia. Psychiatry Research, 23, 99110.
Keepers, G. A., Clappison, V. J. & Casey, D. E. (1983) Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Archives of General Psychiatry, 40, 11131117.
Kenny, J. T. & Meltzer, H. Y. (1991) Attention and higher cortical functions in schizophrenia on semantic memory. Journal of Neuropsychiatry and Clinical Neurosciences, 3, 269275.
Krupp, P. & Barnes, P. (1989) Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology, 99, S118S121.
Lehman, A. F. (1983) The well-being of chronic mental patients: assessing their quality of life. Archives of General Psychiatry, 40, 369373.
Lieberman, J., Johns, C., Cooper, T., et al (1989) Clozapine pharmacology and tardive dyskinesia. Psychopharmacology, 99, S54S59.
Lindström, L. H. (1988) The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatrica Scandinavica, 77, 524529.
Meltzer, H. Y. & Luchins, D. J. (1984) Effect of clozapine in severe tardive dyskinesia: a case report. Journal of Clinical Psychopharmacology, 4, 286287.
Meltzer, H. Y., Bastani, B., Kwon, K. Y., et al (1989) A prospective study of clozapine in treatment-resistant patients: I: Preliminary report. Psychopharmacology, 99, S68S72.
Meltzer, H. Y., Burnett, S., Bastani, B., et al (1990) Effect of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hospital and Community Psychiatry, 41, 892897.
Overall, J. E. & Gorham, D. R. (1962) Brief Psychiatric Rating Scale. Psychological Reports, 10, 799812.
Patterson, T. (1987) Studies toward the subcortical pathogenesis of schizophrenia. Schizophrenia Bulletin, 13, 555576.
Perlick, D., Stastny, P., Katz, U., et al (1986) Memory deficits and anticholinergic levels in chronic schizophrenia. American Journal of Psychiatry, 143, 230232.
Povlsen, J. U., Noring, U., Fog, R., et al (1985) Tolerability of therapeutic effect of clozapine: a retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatrica Scandinavica, 71, 176195.
Safferman, A., Lieberman, J. A., Kane, J. M., et al (1991) Update on clinical efficacy and side effects of clozapine. Schizophrenia Bulletin, 17, 247262.
Seidman, L. J. (1983) Schizophrenic and brain dysfunction: an integration of recent neurodiagnostic findings. Psychology Bulletin, 94, 195238.
Shopsin, B., Klein, H., Aaronson, M., et al (1979) Clozapine, chlorpromazine, and placebo in newly hospitalized acutely schizophrenic patients. Archives of General Psychiatry, 36, 657664.
Spohn, H. E. & Strauss, M. E. (1989) Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. Journal of Abnormal Psychology, 98, 367380.
Strauss, J. S. & Carpenter, W. T. (1972) The prediction of outcome in schizophrenia: I. Characteristics of outcome. Archives of General Psychiatry, 21, 734746.
Strauss, J. S., Carpenter, W. T. & Bartko, J. J. (1974) The diagnosis and understanding of schizophrenia: III. Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophrenia Bulletin, 1, 6169.
Strauss, J. S. & Carpenter, W. T. (1978) The prognosis of schizophrenia: rationale for a multidimensional concept. Schizophrenia Bulletin, 4, 5667.
Van Putten, T. & Marder, S. R. (1974) Behavioral toxicity of antipsychotic drugs. Journal of Clinical Psychiatry, 48, 1319.

Related content

Powered by UNSILO

Dimensions of Outcome with Clozapine

  • Herbert Y. Meltzer (a1)


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.

Dimensions of Outcome with Clozapine

  • Herbert Y. Meltzer (a1)
Submit a response


No eLetters have been published for this article.


Reply to: Submit a response

Your details

Conflicting interests

Do you have any conflicting interests? *